术前化疗对小细胞肺癌远期生存的影响  

Preoperative chemotherapy for long-term results of small cell lung cancer

作　　者：段勇[1] 白连启[1] 龚昌帆[1] 阎东杰[1] 窦学军[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所北京胸科医院胸外科,101149

出　　处：《中华医学杂志》2009年第31期2199-2201,共3页National Medical Journal of China

摘　　要：目的观察术前化疗联合外科手术治疗对小细胞肺癌（SCLC）长期生存的影响。方法总结北京市结核病胸部肿瘤研究所1994年1月至2005年1月手术切除的263例SCLC的综合治疗效果。比较术前化疗组（A组，n=111例）和术后化疗组（B组，n=96例）的治疗效果。结果全组5年生存率42．16％。A组5年生存率38．25％，B组5年生存46．57％。A组5年生存率Ⅰ期60．15％、Ⅱ期35．70％、Ⅲa期40．16％、Ⅲb期14．29％、Ⅳ期0，A组5年生存率NO-1和N2为40．12％和39．22％。B组5年生存率Ⅰ期61．10％、Ⅱ期50．23％、Ⅲa期42．32％、Ⅲb期26．47％、Ⅳ期0，B组5年生存率N0—1和N2组为51．91％和42．69％。结论术前化疗病例比术后化疗病例有预后变差倾向；SCLC要取得较好的治疗效果，手术＋术后化疗模式不可缺少。Objective To reveal the pre-operative chemotherapy for long-term of small cell lung cancer. Methods From January 1994 to January 2005, 263 patients with small cell lung cancer underwent combined therapy. The comparison of long-term survival rates was made between pre-operative chemotherapy group （ n = 111 ） （ group A） and post-operative chemotherapy （ n = 96 ） （ group B）. Results The analyses disclosed that the overall 5-year survival rate was 42. 16%. The 5-year survival rate of group A was 38. 25% while in group B it was 46. 57% . 5-year survival rate of group A for N0-1 and N2 was 40. 12% and 39.22%, that for stage Ⅰ , Ⅱ, Ⅲa, Ⅲb, Ⅳ was 60.15%, 35.70%, 40.16%, 14. 29% and 0 respectively. 5-year survival rate of group B for N0-1 and N2 was 51.91% and 42. 69%, that for stage Ⅰ , Ⅱ , Ⅲ a, Ⅲ b, Ⅳ was 61.1% , 50. 23% , 42. 32% , 26. 47% and 0 respectively. Conclusion The comparison of the survival rate between patients with the pre-operative chemotherapy and those with chemotherapy post-operatively revealed trend of variation. Operation plus post-operative chemotherapy mode is indispensable for better prognosis of small cell lung cancer.

关 键 词：肺肿瘤 药物疗法 联合 术前用药法 

分 类 号：R686[医药卫生—骨科学]